StemCells slashes staff and halts an ocular program; Microlin pulls off a reverse merger;

@FierceBiotech: Columbia U. scientists spotlight a promising proteasome approach in preventing Alzheimer's. FierceBiotechResearch article | Follow @FierceBiotech

@JohnCFierce: I don't get to mention baseball much in my work. Today I get the Mets. More from FierceBiotechResearch | Follow @JohnCFierce

@DamianFierce: hashtag infinitesimal innovation. More from Forbes | Follow @DamianFierce

> StemCells ($STEM) is laying off 25% of its staff and halting the development of a Phase II macular degeneration trial, shifting its focus to a treatment for chronic spinal cord injury. More

> Microlin Bio has backed its way onto Wall Street, reverse merging with American Boarding Company to trade on the OTC market under the symbol "AMIB." News

> Arizona biotech Cancer Prevention Pharmaceuticals is looking to pull off a $29 million IPO to fund its work on treatments for colorectal cancer. Story

Medical Device News

@FierceMedDev: ICYMI yesterday: Study: Boston Sci's Watchman more cost-effective than drugs in the long term. Article | Follow @FierceMedDev

@EmilyWFierce: ICYMI yesterday: Olympus played down early report of superbug infections linked to duodenoscope devices. Report | Follow @EmilyWFierce

@VarunSaxena2: UPDATED: Medical device tax suspended in $1.8T federal budget. Story | Follow @VarunSaxena2

> Italian orthopedic implant maker Lima trades hands from one investor to another. Story

> U.K. scientists roll out computer program for drug-resistant bacteria Dx. Report

> Theranos blows its top over WSJ reports on proprietary testing. Article

Pharma News

@FiercePharma: Sun Pharma said to be in talks to buy Intas for $2.3B. FiercePharmaAsia report | Follow @FiercePharma

@EricPFierce: Bulgarian vet drug company Huvepharma picks up 3 plants from Zoetis for $40M. Article | Follow @EricPFierce

@CarlyHFierce: ICYMI yesterday: With FDA nod, Actelion adds blockbuster hopeful Uptravi to PAH portfolio. More | Follow @CarlyHFierce

> Amgen's PCSK9 outcomes trial to deliver data sooner than expected. Item

> Doctors target Catalyst Pharma's forthcoming pricing on old-turned-new med Firdapse. Report

> Celgene opens door for early launch of Revlimid generics. Article

Biotech Research News

> Moneyball's analytics wiz DePodesta joins Scripps' Big Data team. News

> Transatlantic research team spotlights promise of mTOR drugs for follicular lymphoma. Report

> An intriguing anti-aging drug target may also work on PTSD. Story

> Candidate Clinton calls for $2B in annual Alzheimer's R&D support. Item

> Columbia U. scientists spotlight a promising proteasome approach in preventing Alzheimer's. Article

Vaccines News

> In $171M deal, Bavarian Nordic and J&J's Janssen extend efforts to HPV. More

> GlaxoSmithKline launched new e-commerce platform for vaccines, pharma products. Story

> Vaxart initiates PhI trial of oral influenza B vaccine. Item

> European MERS vaccine effective in camels. Report

> Sanofi's dengue vaccine gets first Asian approval with more discussions underway. Article

Pharma Marketing News

> Going beyond smiling, happy patients: Is better creative on the pharma horizon? More

> Celgene buries the hatchet with India's Natco over generic Revlimid. Item

> Price and reputation are indubitably, inexorably intertwined. Report

> Outcome-based healthcare needs outcome-based marketing. Article

> Pharma marketers steer through changing tides. Story

Suggested Articles

The inclusion of Kupffer cells in in vitro hepatic cultures provides researchers with advanced tools for disease modeling and drug discovery.

A delay to Moderna's phase 3 COVID-19 study is part of a trend of tensions in the biotech’s relationship with the U.S. government, Reuters reported.

GlaxoSmithKline is continuing its strategy of giving out access to its vaccine platform as it adds Medicago to its growing partners list.